Lilly
 
2Q Revenues: $5.6 billion (-10%)
 
2Q Earnings: $923.6 million (-23%)
 
YTD Revenues: $11.2 billion (-7%)
 
YTD Earnings: $1.9 billion (-14%)
 
Comments: U.S. sales were down 10% to $3.0 billion and revenue outside the U.S. was down 11% to $2.6 billion due to the loss of patent exclusivity for Zyprexa (-73%). Cymbalta revenue increased 22% to $1.2 billion. Alimta sales were $659.5million (+8%). Humalog sales were $613.4 million (+4%). Cialis sales were down 2% to $469.5 million. Forteo sales were up 20% to $276.4 million. Effient sales were up 55% to $111 million.